Access to neurological diagnostics often depends on specialized equipment, trained technicians, and hospital-based testing. In 2026, Zeto received FDA 510(k) clearance for its New Wave EEG system, designed for outpatient clinics and home-based care. The clearance marks a recent milestone for the company as it continues to expand its neurodiagnostic platform and research initiatives.
In 2026, Zeto received FDA 510(k) clearance for its New Wave EEG system. The system is designed for use in outpatient clinics and home-based care settings. According to the company, the platform simplifies EEG setup and streamlines testing workflows.
EEG System Designed for Outpatient and Home-Based Care
The Zeto New Wave EEG system is intended to support neurological diagnostics outside traditional hospital environments. The platform is designed to make EEG testing more accessible across outpatient and home-based settings while helping providers manage growing demand for brain health services.
The FDA clearance marks a recent regulatory milestone for the company and expands the use of its EEG technology platform.
Zeto Expands Cloud-Connected Neurodiagnostic Platform
In addition to the FDA clearance, Zeto continues to expand its cloud-connected neurodiagnostic platform. The platform enables remote access to EEG studies and supports the interpretation of EEG data through connected workflows.
The company’s neurodiagnostic ecosystem combines EEG hardware with cloud-based technology designed to support clinical operations and data access.
Clinical Trial Sponsorship Program Supports EEG Research
Zeto also announced the recipients of its 2026 Clinical Trial Sponsorship Program. The program supports research focused on EEG applications in stroke, delirium, and epilepsy care.
The sponsored studies are intended to explore the use of EEG technology across these neurological conditions and contribute to ongoing clinical research efforts.
Recent Developments at Zeto
The FDA 510(k) clearance for the New Wave EEG system, the expansion of the company’s cloud-connected neurodiagnostic platform, and the launch of its 2026 Clinical Trial Sponsorship Program represent recent developments for Zeto.
Please note: Zeto is a company listed on the Propel(x) platform. No syndicate was formed.
